d-glutamate, also known as D-glutamic acid, is a non-proteinogenic amino acid isomer of L-glutamate. It is not typically found in proteins but plays a significant role in various biological processes.
d-glutamate is synthesized through enzymatic reactions involving the racemization of L-glutamate. This process can occur in certain bacteria and mammalian tissues, but the exact mechanisms and significance are still being investigated.
d-glutamate has been shown to exhibit diverse effects, including:
- **Neurological effects:** d-glutamate can act as a neurotransmitter and modulate neuronal activity, although its specific role in the central nervous system is not fully understood.
- **Immunological effects:** d-glutamate can stimulate immune responses and influence the activity of immune cells.
- **Metabolic effects:** d-glutamate can participate in metabolic pathways and influence the production of other amino acids and metabolites.
d-glutamate is studied for various reasons:
- **Understanding its role in biological processes:** Its involvement in neurotransmission, immunity, and metabolism necessitates further research to elucidate its specific functions and mechanisms.
- **Potential therapeutic applications:** d-glutamate's ability to modulate neuronal and immune activity suggests its potential as a therapeutic agent for various conditions, including neurological disorders and autoimmune diseases.
- **Investigating its potential toxicity:** While d-glutamate has shown therapeutic potential, its effects can also be detrimental in high concentrations. Research aims to understand its toxicity profile and develop safe and effective therapeutic strategies.
Current research focuses on unraveling d-glutamate's specific roles in various biological processes, exploring its therapeutic potential, and investigating its safety and toxicity. Understanding d-glutamate's multifaceted nature is crucial for advancing our knowledge of its role in health and disease.'
ID Source | ID |
---|---|
PubMed CID | 23327 |
CHEMBL ID | 76232 |
CHEBI ID | 15966 |
CHEBI ID | 53375 |
SCHEMBL ID | 43222 |
MeSH ID | M0028011 |
Synonym |
---|
CHEBI:15966 , |
d-glutaminsaeure |
(2r)-2-aminopentanedioic acid |
glutamic acid d-form |
DGL , |
(r)-2-aminopentanedioic acid |
BIOMOL-NT_000169 |
c5h9no4 |
PDSP2_001470 |
lopac-g-2128 |
NCGC00015470-01 |
tocris-0217 |
NCGC00024501-01 |
PDSP1_000131 |
r-(-)-glutamic acid |
nsc-77686 |
d-2-aminopentanedioic acid |
glutamic acid, d- |
BPBIO1_001130 |
PDSP2_000130 |
C00217 |
d-2-aminoglutaric acid |
d-glutamic acid , |
d-glu |
6893-26-1 |
d-glutamate |
d-glutaminic acid |
d-glutamic acid, >=99% (tlc) |
DB02517 |
NCGC00024501-03 |
NCGC00024501-02 |
PDSP1_001486 |
d-[14c]glu |
bdbm26431 |
chembl76232 , |
CHEBI:53375 |
h-d-glu-oh |
G0057 |
gammadpga |
EN300-78764 |
dtxsid1048675 , |
tox21_113052 |
cas-6893-26-1 |
dtxcid1028601 |
l(+)-glutamic acid |
einecs 230-000-8 |
ai3-09072 |
unii-q479989wea |
q479989wea , |
nsc 77686 |
(r)-1-aminopropane-1,3-dicarboxylic acid |
(r)-glutamic acid |
d-(-)-glutamic acid |
AM20100640 |
glutamic acid d-form [mi] |
AKOS015854118 |
gtpl4708 |
SCHEMBL43222 |
NCGC00024501-04 |
AC-15064 |
r-(?)-1-aminopropane-1,3-dicarboxylic acid |
Q-100774 |
glutamic acid # |
d-glutamicacid |
138-16-9 |
(r)-1-aminopropane-1,3-dicarboxylic acid |
HB0243 |
AC-24113 |
mfcd00063112 |
d-glutamic acid, >=99% |
M02964 |
SR-01000597732-1 |
sr-01000597732 |
delta-glutamic acid |
r-(-)-glutamate |
delta-glutaminic acid |
delta-glutaminsaeure |
lopac-gamma-2128 |
delta-2-aminopentanedioate |
delta-glutamate |
delta-2-aminopentanedioic acid |
d-2-aminopentanedioate |
(r)-2-aminopentanedioate |
d-2-aminoglutarate |
delta-glutaminate |
delta-2-aminoglutaric acid |
delta-2-aminoglutarate |
d-glutamic acid, vetec(tm) reagent grade, >=99% |
HY-100805 |
CS-6255 |
Q27077040 |
AS-12791 |
(r)-2-aminopentanedioicacid |
Z1741982700 |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Product Category | Products |
---|---|
Vitamins & Supplements | 2 |
Product | Brand | Category | Compounds Matched from Ingredients | Date Retrieved |
---|---|---|---|---|
Emerald Labs Reflux Health -- 60 Vegetable Caps | Emerald Labs | Vitamins & Supplements | Lipase, Cellulase, DGL | 2024-11-29 10:47:42 |
NutriBiotic Throat Spray -- 4 fl oz | NutriBiotic | Vitamins & Supplements | DGL, glycerin | 2024-11-29 10:47:42 |
Role | Description |
---|---|
Escherichia coli metabolite | Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. |
mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
D-alpha-amino acid | |
glutamic acid | An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 39.8107 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.4513 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
USP1 protein, partial | Homo sapiens (human) | Potency | 15.8489 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
TDP1 protein | Homo sapiens (human) | Potency | 24.8446 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
AR protein | Homo sapiens (human) | Potency | 26.8325 | 0.0002 | 21.2231 | 8,912.5098 | AID743035 |
cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0020 | 7.5337 | 39.8107 | AID891 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 0.0010 | 6.0009 | 35.4813 | AID943 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 22.1061 | 0.0200 | 10.7869 | 31.6228 | AID912 |
pyruvate kinase PKM isoform b | Homo sapiens (human) | Potency | 0.0050 | 2.5119 | 12.2628 | 25.1189 | AID954; AID958 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Glutamate receptor 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 100.0000 | 0.0001 | 1.6179 | 10.0000 | AID92501 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 100.0000 | 0.0001 | 1.7000 | 10.0000 | AID92501 |
Glutamate receptor 3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 100.0000 | 0.0001 | 1.7000 | 10.0000 | AID92501 |
Glutamate receptor 4 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 100.0000 | 0.0001 | 1.7000 | 10.0000 | AID92501 |
Excitatory amino acid transporter 1 | Homo sapiens (human) | IC50 (µMol) | 1,000.0000 | 0.1200 | 89.3825 | 1,000.0000 | AID1745862 |
Glutamate racemase | Helicobacter pylori 26695 | Ki | 33,555.6000 | 5.8000 | 5.8000 | 5.8000 | AID327298; AID327316; AID327317 |
Alpha-ketoglutarate-dependent dioxygenase FTO | Homo sapiens (human) | IC50 (µMol) | 1,000.0000 | 3.0000 | 6.1000 | 9.8000 | AID734755 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Metabotropic glutamate receptor 6 | Homo sapiens (human) | EC50 (µMol) | 1,000.0000 | 0.0550 | 2.2786 | 4.9000 | AID107252 |
Metabotropic glutamate receptor 1 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 10.0000 | 0.2000 | 4.4946 | 10.0000 | AID108501 |
Metabotropic glutamate receptor 2 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 4.0000 | 0.0006 | 1.4262 | 7.7000 | AID108977 |
Metabotropic glutamate receptor 3 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 9.0000 | 0.0021 | 1.8909 | 9.0000 | AID109171 |
Metabotropic glutamate receptor 4 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 56.0000 | 0.0090 | 2.5440 | 9.4900 | AID109467; AID246695 |
Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 4.4000 | 0.0015 | 1.6537 | 10.0000 | AID107065 |
Metabotropic glutamate receptor 6 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 20.0000 | 0.0550 | 2.4030 | 7.6000 | AID107241 |
Metabotropic glutamate receptor 7 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 5,400.0000 | 0.1460 | 0.8230 | 1.5000 | AID107264 |
Metabotropic glutamate receptor 1 | Homo sapiens (human) | EC50 (µMol) | 1,000.0000 | 0.2000 | 4.4100 | 9.3000 | AID108645 |
Metabotropic glutamate receptor 2 | Homo sapiens (human) | EC50 (µMol) | 1,000.0000 | 0.0006 | 1.1784 | 8.5000 | AID109003 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Carbonic anhydrase 1 | Homo sapiens (human) | KA | 10.7000 | 0.0200 | 1.7219 | 7.4000 | AID1397319 |
Carbonic anhydrase 2 | Homo sapiens (human) | KA | 100.0000 | 0.0110 | 1.4273 | 7.8000 | AID1397320 |
Carbonic anhydrase-like protein, putative | Trypanosoma cruzi strain CL Brener | KA | 100.0000 | 0.1400 | 2.8050 | 7.5400 | AID1397322 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID26351 | pKa value was determined | 1982 | Journal of medicinal chemistry, Dec, Volume: 25, Issue:12 | Methotrexate analogues. 16. Importance of the side-chain amide carbonyl group as a structural determinant of biological activity. |
AID39376 | In vitro binding affinity against synaptic membrane from rat brain using [3H](R)-Asp as the radioligand | 1989 | Journal of medicinal chemistry, Oct, Volume: 32, Issue:10 | Excitatory amino acid agonists. Enzymic resolution, X-ray structure, and enantioselective activities of (R)- and (S)-bromohomoibotenic acid. |
AID327309 | Activity of Helicobacter pylori MurI A75T mutant | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID1372624 | Binding affinity to Mycobacterium tuberculosis glutamate racemase assessed as change in melting temperature by SYPRO orange dye based fluorescence assay | 2018 | Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1 | Lead identification and optimization of bacterial glutamate racemase inhibitors. |
AID327308 | Activity of Helicobacter pylori MurI | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID109467 | Effect on Metabotropic glutamate receptor 4 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. |
AID107241 | Effect on Metabotropic glutamate receptor 6 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. |
AID1397322 | Activation of Trypanosoma cruzi CA preincubated for 15 mins followed by CO2 addition by stopped-flow assay | |||
AID107264 | Effect on Metabotropic glutamate receptor 7 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. |
AID93714 | In vitro binding affinity against synaptic membrane from rat brain using [3H]KAIN as the radioligand | 1989 | Journal of medicinal chemistry, Oct, Volume: 32, Issue:10 | Excitatory amino acid agonists. Enzymic resolution, X-ray structure, and enantioselective activities of (R)- and (S)-bromohomoibotenic acid. |
AID1397319 | Activation of human CA1 by stopped-flow CO2 hydration assay | |||
AID92796 | In vitro binding affinity against synaptic membrane from rat brain using [3H]-Ionotropic glutamate receptor AMPA as the radioligand | 1989 | Journal of medicinal chemistry, Oct, Volume: 32, Issue:10 | Excitatory amino acid agonists. Enzymic resolution, X-ray structure, and enantioselective activities of (R)- and (S)-bromohomoibotenic acid. |
AID179582 | In vitro binding affinity against synaptic membrane from rat brain using [3H](S)-Glu as the radioligand | 1989 | Journal of medicinal chemistry, Oct, Volume: 32, Issue:10 | Excitatory amino acid agonists. Enzymic resolution, X-ray structure, and enantioselective activities of (R)- and (S)-bromohomoibotenic acid. |
AID109003 | Agonistic activity at mGlu2 receptor expressed in CHO cells | 1996 | Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16 | A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid. |
AID327316 | Inhibition of Helicobacter pylori MurI A75T mutant | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID109171 | Effect on Metabotropic glutamate receptor 3 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. |
AID327314 | Activity of Staphylococcus aureus MurI | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID1397321 | Activation of Leishmania donovani chagasi CA preincubated for 15 mins followed by CO2 addition by stopped-flow assay | |||
AID107065 | Effect on Metabotropic glutamate receptor 5 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. |
AID246695 | Stimulation of [3H]phosphatidylinositol accumulation by rat Metabotropic glutamate receptor 4 co-expressed with Gqi9 protein in HEK 293 cells; Active | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7 | Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. |
AID1397320 | Activation of human CA2 by stopped-flow CO2 hydration assay | |||
AID327313 | Activity of Enterococcus faecium MurI | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID327311 | Activity of Escherichia coli MurI | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID1912477 | Inhibition of the Excitatory Amino Acid Transporter 1 (EAAT1, SLC1A3) as assessed by a phenotypic impedance-based assay detecting changes in cell morphology by L-glutamate uptake in HEK-293 JumpIN-SLC1A3 cells (PubChem AID: 1745862) | |||
AID327312 | Activity of Enterococcus faecalis MurI | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID108977 | Effect on Metabotropic glutamate receptor 2 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. |
AID107252 | Agonistic activity at mGlu6 receptor expressed in CHO cells | 1996 | Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16 | A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid. |
AID328866 | Binding affinity to Pyrococcus horikoshii sodium-coupled aspartate transporter | 2007 | Nature, Jan-25, Volume: 445, Issue:7126 | Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. |
AID246893 | In vitro activity to inhibit MCP-1-induced leukocyte migration of THP-1 cells | 2005 | Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3 | Identification of 3-(acylamino)azepan-2-ones as stable broad-spectrum chemokine inhibitors resistant to metabolism in vivo. |
AID108645 | Agonistic activity at mGlu1-alpha receptor expressed in CHO cells | 1996 | Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16 | A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid. |
AID327298 | Inhibition of Helicobacter pylori glutamate racemase | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID734755 | Inhibition of human hexahistidine-tagged full-length FTO expressed in Escherichia coli BL21 (DE3) using 3-methylthymidine as substrate assessed as inhibition of 3-methylthymidine conversion to thymidine after 1 hr by liquid chromatographic analysis | 2013 | Journal of medicinal chemistry, May-09, Volume: 56, Issue:9 | Structural basis for inhibition of the fat mass and obesity associated protein (FTO). |
AID109484 | Agonistic activity at mGlu4a receptor expressed in CHO cells | 1996 | Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16 | A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid. |
AID327310 | Activity of Helicobacter pylori MurI E151K mutant | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID92501 | Tested for inhibition of Specific DL-[H]Ionotropic glutamate receptor AMPA binding to rat brain membranes | 1983 | Journal of medicinal chemistry, Jun, Volume: 26, Issue:6 | Enzymic resolution and binding to rat brain membranes of the glutamic acid agonist alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. |
AID108501 | Effect on Metabotropic glutamate receptor 1 | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | (S)-homo-AMPA, a specific agonist at the mGlu6 subtype of metabotropic glutamic acid receptors. |
AID327317 | Inhibition of Helicobacter pylori MurI E151K mutant | 2007 | Nature, Jun-14, Volume: 447, Issue:7146 | Exploitation of structural and regulatory diversity in glutamate racemases. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (16.67) | 18.7374 |
1990's | 2 (11.11) | 18.2507 |
2000's | 4 (22.22) | 29.6817 |
2010's | 4 (22.22) | 24.3611 |
2020's | 5 (27.78) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.07) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |